scholarly journals The Role of Actin in Muscle Spasms in a Case Series of Patients with Advanced Basal Cell Carcinoma Treated with a Hedgehog Pathway Inhibitor

2020 ◽  
Author(s):  
Natalie Teh ◽  
Liang Joo Leow
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Case Series ◽  
Hedgehog Pathway ◽  
Muscle Spasms ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

2016 ◽  
Vol 21 (10) ◽  
pp. 1218-1229 ◽  
Author(s):  
Mario E. Lacouture ◽  
Brigitte Dréno ◽  
Paolo Antonio Ascierto ◽  
Reinhard Dummer ◽  
Nicole Basset‐Seguin ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

2014 ◽  
Vol 70 (1) ◽  
pp. 60-69 ◽  
Author(s):  
Anne Lynn S. Chang ◽  
James A. Solomon ◽  
John D. Hainsworth ◽  
Leonard Goldberg ◽  
Edward McKenna ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Expanded Access ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol

2021 ◽  
Author(s):  
Vincenzo De Giorgi ◽  
Luciana Trane ◽  
Giulia Pieretti ◽  
Nicola Santoro ◽  
Flavia Silvestri ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Delayed Diagnosis ◽  
Case Series ◽  
Hedgehog Pathway ◽  
Single Center ◽  
Management Protocol ◽  
Advanced Basal Cell Carcinoma

Background: The management of difficult-to-treat periocular basal cell carcinoma becomes very challenging in cases of delayed diagnosis, leading to the development of locally advanced basal cell carcinoma.Objective: The aim of this study was to evaluate the outcomes of Hedgehog pathway inhibitors (vismodegib and sonidegib)  treatment in patients affected by periocular locally advanced basal cell carcinoma. We focused on the common adverse events  and their correlation with the administration schedule  in order to determine a management protocol specific for the periocular area.Methods:  This observational prospective study included a single-center case series with patients who were histologically confirmed to have periocular or orbital locally advanced basal cell carcinoma,  treated with Hedgehog pathway inhibitors.Results: All patients benefitted in terms of regression or stabilization of the neoplasm. In the first months of treatment, the HPIs were well tolerated, and the first important side effects appeared after about 5 months of continuous use of the drug.Conclusion: These data could lead to a new type of therapeutic scheme where neoadjuvant therapy could be followed by pulse therapy as an adjuvant to surgery.

Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9532-9532 ◽  
Author(s):  
Johan Hansson ◽  
Axel Hauschild ◽  
Rainer Kunstfeld ◽  
Jean Jacques Grob ◽  
Brigitte Dréno ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Primary Analysis ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document